The Observation Of Safety And Survival Of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Combined With Anti-hepatitis B Virus Therapy
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
6 months
Yes
jinglin xia, MD
Principal Investigator
Liver cancer institute, Zhongshan Hospital
China: Food and Drug Administration
LCI-001
NCT01102335
April 2010
December 2012
Name | Location |
---|